ReproCELL Inc (4978) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

ReproCELL Inc (4978) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH218283D
  • |
  • Pages: 47
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

ReproCELL Inc (ReproCELL) is a biotechnology company that develops and commercializes stem cell technologies. The company offers products in divisions such as research reagents, cultivation materials, and cell and biorepository. Its research reagent products include hES iPSC culture reagents, human HSC culture reagent, reprogramming regent for iPSC, small molecule, pluripotency marker, and culture reagents for cancer research. ReproCELL's cell and biorepository products comprise human iPS cells derived cardiomyocytes, hiPSC-neurons, hiPSC-hepatocytes, hiPSC-disease model cells and biorepository. The company markets its products across Japan. ReproCELL is headquartered in Yokohama, Japan.

ReproCELL Inc (4978)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ReproCELL Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

ReproCELL Inc, Medical Devices Deals, 2012 to YTD 2018 10

ReproCELL Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

ReproCELL Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

ReproCELL Acquires Induced Pluripotent Stem Cell Business from Stemgent for USD8.5 Million 13

Stemgent Completes Acquisition Of Human Tissue Business From Asterand For USD 9 Million 14

Venture Financing 15

Kringle Pharma Raises USD5.4 Million in Venture Financing 15

Reinnervate Secures USD0.16 Million in Venture Funding 17

Reinnervate Secures USD1.72 Million in Venture Funding 18

Stemgent Raises USD 11.3 Million In Venture Financing 19

Stemgent Raises USD 6.3 Million In Series C Financing 20

Partnerships 21

Q Therapeutics Forms Joint Venture with REPROCELL 21

Q Therapeutics Announces Research Agreement with ReproCELL 22

ReproCELL and Fox Chase Cancer Center Enter into Partnership 23

n3D Biosciences Enters into Distribution Agreement with ReproCELL for Three-Dimensional Bioprinting Product Lines 24

n3D Biosciences Enters into Distribution Agreement with ReproCELL for Cell Culture Products 25

ReproCELL Enters Into Distribution Agreement With Laboratorios Conda 26

Reinnervate Enters Into Co-Development Agreement With Roslin Cellab 27

Reinnervate Enters Into Co-Development Agreement With Roslin Cellab 28

Reinnervate Enters Into Co-Development Agreement With Kirkstall 29

Licensing Agreements 30

ReproCELL Receives Rights of Stemchymal Cell Therapy Technology from Steminent Biotherapeutics 30

Stemgent Enters Into Licensing Agreement With iPS Academia For Induced Pluripotent Stem Cell Patent Portfolio 31

Equity Offering 32

ReproCELL Completes IPO For USD 20.8 Million 32

Asset Transactions 34

ReproCELL to Sell ReproHP Medium 34

ReproCELL Acquires Induced Pluripotent Stem Cell Business from Stemgent for USD8.5 Million 35

Acquisition 36

ReproCELL Acquires BioServe Biotech from Cancer Genetics for USD1.9 Million 36

ReproCELL Plans to Acquire 7.44% Stake in ReproCELL USA 37

ReproCELL to Acquire Biopta for USD8.2 Million 38

ReproCELL Acquires BioServe Biotechnologies 40

ReproCELL Acquires Reinnervate 41

ReproCELL Inc-Key Competitors 42

ReproCELL Inc-Key Employees 43

ReproCELL Inc-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Joint Venture 45

Recent Developments 46

Other Significant Developments 46

Jun 21, 2018: Human Tissue Experts REPROCELL Launch New Customized Primary Cell Isolation Services 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47

List of Figures

ReproCELL Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ReproCELL Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

ReproCELL Inc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

ReproCELL Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ReproCELL Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ReproCELL Inc, Deals By Therapy Area, 2012 to YTD 2018 9

ReproCELL Inc, Medical Devices Deals, 2012 to YTD 2018 10

ReproCELL Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

ReproCELL Acquires Induced Pluripotent Stem Cell Business from Stemgent for USD8.5 Million 13

Stemgent Completes Acquisition Of Human Tissue Business From Asterand For USD 9 Million 14

Kringle Pharma Raises USD5.4 Million in Venture Financing 15

Reinnervate Secures USD0.16 Million in Venture Funding 17

Reinnervate Secures USD1.72 Million in Venture Funding 18

Stemgent Raises USD 11.3 Million In Venture Financing 19

Stemgent Raises USD 6.3 Million In Series C Financing 20

Q Therapeutics Forms Joint Venture with REPROCELL 21

Q Therapeutics Announces Research Agreement with ReproCELL 22

ReproCELL and Fox Chase Cancer Center Enter into Partnership 23

n3D Biosciences Enters into Distribution Agreement with ReproCELL for Three-Dimensional Bioprinting Product Lines 24

n3D Biosciences Enters into Distribution Agreement with ReproCELL for Cell Culture Products 25

ReproCELL Enters Into Distribution Agreement With Laboratorios Conda 26

Reinnervate Enters Into Co-Development Agreement With Roslin Cellab 27

Reinnervate Enters Into Co-Development Agreement With Roslin Cellab 28

Reinnervate Enters Into Co-Development Agreement With Kirkstall 29

ReproCELL Receives Rights of Stemchymal Cell Therapy Technology from Steminent Biotherapeutics 30

Stemgent Enters Into Licensing Agreement With iPS Academia For Induced Pluripotent Stem Cell Patent Portfolio 31

ReproCELL Completes IPO For USD 20.8 Million 32

ReproCELL to Sell ReproHP Medium 34

ReproCELL Acquires Induced Pluripotent Stem Cell Business from Stemgent for USD8.5 Million 35

ReproCELL Acquires BioServe Biotech from Cancer Genetics for USD1.9 Million 36

ReproCELL Plans to Acquire 7.44% Stake in ReproCELL USA 37

ReproCELL to Acquire Biopta for USD8.2 Million 38

ReproCELL Acquires BioServe Biotechnologies 40

ReproCELL Acquires Reinnervate 41

ReproCELL Inc, Key Competitors 42

ReproCELL Inc, Key Employees 43

ReproCELL Inc, Other Locations 44

ReproCELL Inc, Subsidiaries 44

ReproCELL Inc, Joint Venture 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

ReproCELL Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17745
Site License
USD 500 INR 35490
Corporate User License
USD 750 INR 53235

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com